Program
vorolanib
Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.
Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.
Drug pageVorolanib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticals | 141 open or running | phase 3since Mar 23, 2017 | May 22, 2013 | Jun 2027phase 1 · NCT07809802 |
| EyePoint Pharmaceuticalsits history only | 84 open or running | phase 3since Oct 30, 2024 | Feb 6, 2021 | Oct 2027phase 3 · NCT07449923 |
| Tyrogenexits history only | 20 open or running | phase 2since Jan 21, 2015 | Feb 14, 2011 | none ahead |
Also a collaborator on its studies: SynteractHCR.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Betta Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 22, 2013First study: phase 1 study in Advanced CancerFirst studyNCT01863485 · 44 enrolled · China
- Mar 10, 2015Phase 1 study in Macular DegenerationNCT02452385 · 56 enrolled · China
- Oct 12, 2015Phase 1 study in Renal Cell Carcinoma RecurrentNCT02577458 · 18 enrolled · China
- Jun 9, 2016Named vorolanibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, EYP-1901, CM082
- Mar 23, 2017Phase 3 study in Renal Cell Cancer MetastaticNCT03095040 · 390 enrolled · China
- Sep 15, 2017Phase 1 study in Advanced Gastric CancerNCT03286244 · 21 enrolled · China
- Jul 19, 2018Phase 2 study in Mucosal MelanomaNCT03602547 · 40 enrolled · China
- Oct 15, 2018Phase 2 study in Macular DegenerationNCT03710863 · 64 enrolled · China
- Dec 26, 2018Phase 1 study in Advanced Malignant Solid TumorsNCT03792958 · 19 enrolled · China
- Feb 19, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03848611 · 20 enrolled · China
- Apr 4, 2019Phase 2 study in Small Cell Lung CarcinomaNCT03904719 · 30 enrolled · China
- Jan 7, 2020Phase 1 study in Myopic Choroidal NeovascularisationNCT04222842 · 96 enrolled · China
- Mar 26, 2020Phase 1 study in Advanced Malignant Solid TumorsNCT04328506 · 96 enrolled · China
- Jun 12, 2020Phase 1 study in Advanced Solid TumorNCT04434326 · 4 enrolled · China
- Sep 3, 2026Phase 1 study in Hepatic Impairment (HI)NCT07809802 · 36 planned · China
Ahead
- Jun 2027Primary completion: phase 1 study in Hepatic Impairment (HI)NCT07809802
TargetBeta
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 14 Betta Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07809802Hepatic Impairment (HI) · China | 1 | Recruiting | Jun 2027 | 36 |
| NCT04434326Advanced Solid Tumor · China | 1 | Completed | Oct 22, 2021 | 4 |
| NCT04328506Advanced Malignant Solid Tumors · China | 1 | Completed | Jul 27, 2020 | 96 |
| NCT04222842Myopic Choroidal Neovascularisation · China | 1 | Suspended | Dec 30, 2021 | 96 |
| NCT03904719Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Jun 30, 2021 | 30 |
| NCT03848611Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Feb 2021 | 20 |
| NCT03792958Advanced Malignant Solid Tumors · China | 1 | UNKNOWN | Jun 2023 | 19 |
| NCT03710863Macular Degeneration · China | 2 | UNKNOWN | Jan 1, 2022 | 64 |
| NCT03602547Mucosal Melanoma · China | 2 | UNKNOWN | Jul 2019 | 40 |
| NCT03286244Advanced Gastric Cancer · China | 1 | UNKNOWN | Aug 2019 | 21 |
| NCT03095040Renal Cell Cancer Metastatic · China | 3 | UNKNOWN | Feb 2021 | 390 |
| NCT02577458Renal Cell Carcinoma Recurrent · China | 1 | UNKNOWN | Mar 2018 | 18 |
| NCT02452385Macular Degeneration · China | 1 | Suspended | Jun 2020 | 56 |
| NCT01863485Advanced Cancer · China | 1 | Completed | Oct 2014 | 44 |
How it is read
Names in the registry
- “EYP-1901”, 8 entries
- “CM082”, 5 entries
- “CM082 plus JS001”, 3 entries
- “vorolanib”, 2 entries
- “X-82”, 2 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 7 studies
- Macular Edema, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Diabetic Retinopathy, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.